A biosimilar (also known as a follow-on biologic or subsequent entry biologic) is a product produced by two different pharmaceutical companies that are essentially the same drug. Often times multiple companies will come up with biosimilars but offer them at a lower price in order to be competitive in the market.
This year was particularly brutal for biosimilar appeals; drugs like Cellrion’s Inflectra- nearly identical to Janssen Biotech’s Remicade- was nontheless approved by the FDA.
As the FDA continues to approve and accept safe and effective biosimilars, many have begun to wonder what reception these copycat drugs can expect to receive from prescribing physicians.
According to a survey conducted by the Biosimilars Forum, 91 percent of US physicians said they would be willing to prescribe a biosimilar over its branded biologic. Other results of the survey however, suggested that doctors would benefit from a better education of how the approval process for biosimilars differs from branded drugs, in order to ensure they have the most accurate information to help them make prescribing decisions.